Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

The interleukin-10 gene promoter polymorphism −1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma

Genes & Immunity volume 8, pages 164–167 (2007)Cite this article

Abstract

The Interleukin 10 (IL-10) gene is highly polymorphic, and the IL-10−1087AG (rs1800896) gene variation is the only so far studied intensively in association with certain diseases. Conflicting data have been published about an association of IL-10−1087AG gene variation with lower rates of complete remission and lower overall survival (OS) in patients with diffuse large B-cell lymphoma. To further investigate this in malignant lymphoma, we established the IL-10 genotypes in patients from the NHL-B1/ B2 studies from the German High-Grade Non-Hodgkin's Lymphoma Study Group. In our study, allele frequencies of lymphoma patients are comparable as in healthy controls. No increase of IL-10–1087G alleles was found. In addition we did not find any difference in OS or event-free survival between patients with IL-10–1087AA and the other genotypes. Comparable results were obtained for the IL-10 loci at −3538 (A/T), −1354 (A/G), −824 (C/T) and −597 (A/C) (rs1800890, rs1800893, rs1800871 and rs1800872).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Moore KW, de Waal Malefyt R, Coffman RL et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683–765.

    Article  CAS  Google Scholar 

  2. Cortes JE, Talpaz M, Cabanillas F et al. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 1995; 85: 2516–2520.

    CAS  PubMed  Google Scholar 

  3. Stasi R, Zinzani PL, Galieni P et al. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 1994; 88: 770–777.

    Article  CAS  Google Scholar 

  4. Blay JY, Burdin N, Rousset F et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993; 82: 2169–2174.

    CAS  PubMed  Google Scholar 

  5. Burdin N, Rousset F, Banchereau J . B-cell-derived IL-10: production and function. Methods 1997; 11: 98–111.

    Article  CAS  Google Scholar 

  6. Keystone E, Wherry J, Grint P . IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheumatic Dis Clin 1998; 24: 629–639.

    Article  CAS  Google Scholar 

  7. Ferraccioli G, Falleti E, DeVita S et al. Circulating levels of interleukin 10 and other cytokines in rheumatoid arthritis treated with cyclosporin A or combination therapy. J Rheum 1998; 25: 1874–1879.

    CAS  PubMed  Google Scholar 

  8. Ho M, Schollaardt T, Snape S et al. Endogenous interleukin-10 modulates proinflammatory response in Plasmodium falciparum malaria. J Infect Dis 1998; 178: 520–525.

    Article  CAS  Google Scholar 

  9. Sarris AH, Kliche KO, Pethambaram P et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999; 10: 433–440.

    Article  CAS  Google Scholar 

  10. Goldman M, Velu T, Pretolani M . Interleukin-10. Actions and therapeutic potential. BioDrugs 1997; 7: 6–14.

    Article  CAS  Google Scholar 

  11. Lalani I, Bhol K, Ahmed A . Interleukin-10: biology, role in inflammation and autoimmunity. Ann All Asth Immunol 1997; 79: 469–484.

    Article  CAS  Google Scholar 

  12. Narula SK, Cutler D, Grint P . Immunomodulation of Crohn's disease by Interleukin-10. Agents and Actions Suppl 1998; 49: 57–65.

    CAS  Google Scholar 

  13. Van Deventer SJ . Immunotherapy of Crohn's disease. Scand JImmunol 2000; 51: 18–22.

    Article  CAS  Google Scholar 

  14. Cavet J, Middleton P, Segall M et al. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999; 94: 3941–3946.

    CAS  PubMed  Google Scholar 

  15. Hollegaard MV, Bidwell JL . Cytokine gene polymorphism in human disease: on-line databases, Supplement 3. Genes Immun 2006; 7: 269–276.

    Article  CAS  Google Scholar 

  16. Turner D, Williams D, Sankaran D et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogen 1997; 24: 1–8.

    Article  CAS  Google Scholar 

  17. Westendorp R, Langermans J, Huizinga T et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170–173.

    Article  CAS  Google Scholar 

  18. Gibson AW, Edberg JC, Wu J et al. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001; 166: 3915–3922.

    Article  CAS  Google Scholar 

  19. Eskdale J, Gallagher G, Verweij C et al. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95: 9465–9470.

    Article  CAS  Google Scholar 

  20. Crawley E, Kay R, Sillibourne J et al. Polymorphic haplotypes of the IL-10 5′ flanking region determine variable IL-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthr Rheum 1999; 42: 1101–1108.

    Article  CAS  Google Scholar 

  21. Mormann M, Rieth H, Hua TD et al. Mosaics of gene variations in the Interleukin-10 gene promoter affect interleukin-10 production depending on the stimulation used. Genes Immun 2004; 5: 246–255.

    Article  CAS  Google Scholar 

  22. Lech-Maranda E, Baseggio L, Bienvenu J et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004; 103: 3529–3534.

    Article  CAS  Google Scholar 

  23. Berglund M, Thunberg U, Roos G et al. The interleukin-10 gene promoter polymorphism (−1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood 2005; 105: 4894–4895 and author reply 4895.

    Article  CAS  Google Scholar 

  24. Rothman N, Skibola CF, Wang SS et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006; 7: 27–38.

    Article  CAS  Google Scholar 

  25. Nieters A, Beckmann L, Deeg E et al. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006; 7: 615–624.

    Article  CAS  Google Scholar 

  26. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641.

    Article  CAS  Google Scholar 

  27. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626–633.

    Article  CAS  Google Scholar 

  28. Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112: 3754–3762.

    Article  CAS  Google Scholar 

  29. Im SH, Hueber A, Monticelli S et al. Chromatin-level regulation of the IL10 gene in T cells. J Biol Chem 2004; 279: 46818–46825.

    Article  CAS  Google Scholar 

  30. Zhang X, Edwards JP, Mosser DM . Dynamic and transient remodeling of the macrophage IL-10 promoter during transcription. J Immunol 2006; 177: 1282–1288.

    Article  CAS  Google Scholar 

  31. Wang ZY, Sato H, Kusam S et al. Regulation of IL-10 gene expression in Th2 cells by Jun proteins. J Immunol 2005; 174: 2098–2105.

    Article  CAS  Google Scholar 

  32. Shoemaker J, Saraiva M, O'Garra A . GATA-3 directly remodels the IL-10 locus independently of IL-4 in CD4+ T cells. J Immunol 2006; 176: 3470–3479.

    Article  CAS  Google Scholar 

  33. Saraiva M, Christensen JR, Tsytsykova AV et al. Identification of a macrophage-specific chromatin signature in the IL-10 locus. J Immunol 2005; 175: 1041–1046.

    Article  CAS  Google Scholar 

  34. Lucas M, Zhang X, Prasanna V et al. ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol 2005; 175: 469–477.

    Article  CAS  Google Scholar 

  35. Jones EA, Flavell RA . Distal enhancer elements transcribe intergenic RNA in the IL-10 family gene cluster. J Immunol 2005; 175: 7437–7446.

    Article  CAS  Google Scholar 

  36. Lan Q, Zheng T, Rothman N et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006; 107: 4101–4108.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are gratefull to the Deutsche Forschnugsgemeinschaft (Graduiertenkolleg 1034), the BMBF (NGFN-1) and the Deutsche Krebshilfe/BMBF (NHL-B) for supporting this work.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Universitätsmedizin der Georg-August-Universität, Göttingen, Germany

    D Kube, T-D Hua & L Trümper

  2. Department of Statistics and Epidemiology, Institute of Medical Informatics, University of Leipzig, Leipzig, Germany

    M Klöss & M Löffler

  3. Institute of Epidemiology, Universitätsmedizin der Georg-August-Universität, Göttingen, Germany

    B Kulle

  4. Section of Statistics, Institute of Basic Medical Science, University of Oslo, Oslo, Norway

    B Kulle

  5. Department of Pharmacology and Toxicology, Universitätsmedizin der Georg-August-Universität, Göttingen, Germany

    J Brockmöller & L Wojnowski

  6. Institute of Pharmacology, University Mainz, Mainz, Germany

    L Wojnowski

  7. Department of Internal Medicine I, Saarland University, Homburg/Saar for the DSHNHL (German High Grade NHL study group), Mainz, Germany

    M Pfreundschuh

Authors
  1. D Kube
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T-D Hua
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Klöss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Kulle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Brockmöller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Wojnowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Löffler
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Pfreundschuh
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Trümper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Kube.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kube, D., Hua, TD., Klöss, M. et al. The interleukin-10 gene promoter polymorphism −1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma. Genes Immun 8, 164–167 (2007). https://doi.org/10.1038/sj.gene.6364364

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gene.6364364

Keywords

This article is cited by

Search

Advanced search

Quick links